1. Group commercial inflection in FY27 - Management calls FY27 the group's "commercial inflection" point after completing a deliberate investment phase, with consolidated EBITDA already expanding 485% to ₹15.8 cr in FY26. The group expects to turn consolidated PAT positive in FY27, moving from cash burn to self-funded growth.
2. Innoxel first commercial CMO supply - Innoxel's first commercial CMO supply begins Q2 FY27, with two to three CMO products commercialising during the year, after the facility cleared US FDA and EU GMP with zero critical observations. This shifts Innoxel from pure licensing income to recurring manufacturing revenue, with guided FY27 revenue growth of 35-45% and EBITDA margins of 20-25%.
3. Standalone ₹171 cr order book execution - A ₹171 cr order book, including a $27 million tender received in March 2026 with supply already started, gives revenue visibility for FY27. Management guides 10-15% standalone revenue growth and 10-15% EBITDA margins for FY27, with 90% of the delayed tender covered in the year.
4. Innoxel 505(b)(2) filings and profit share - Two 505(b)(2) assets have completed exhibit batches and stability studies; one is filing in Europe imminently with a US filing targeted for Q3 FY27, and the second targets Q4 FY27. Both will be filed in partners' names with active profit share for Innoxel, creating a high-margin royalty stream on top of manufacturing income.
5. Varenyam Healthcare domestic branded scale-up - Varenyam Healthcare grew revenue 13.7% to ₹58.4 cr and turned EBITDA-positive at ₹2.5 cr in FY26, with its top brand Sugammadex crossing ₹10 cr. Management guides 20-25% revenue growth and 8-13% EBITDA margins for FY27, supported by field force expansion to 250, seven new product launches, and a second division in gynecology.
6. Standalone EU GMP and PIC/S inspections - PIC/S and EU GMP inspection at our standalone facilities are scheduled during FY '27, with infrastructural upgrades including ORABS lines and water systems already completed. Clearing these inspections unlocks new regulated geographies in APAC that accept EU GMP-compliant manufacturing, where margins are higher.
7. Innoxel 10 filings and deal pipeline - Innoxel plans 10 filings in FY27 (six own, four CMO) and targets 20 new partner deals, of which 10 are at advanced stages of discussion. With 42 cumulative deals already signed and a pipeline of 42 assets, the growing deal book builds the base for the \~₹750 cr peak revenue target management sets for 2030-31.
8. Varenyam Biolifesciences capex underway - The ₹160 cr greenfield facility for complex injectables targeting Brazil, South Africa, and Australia has \~20% of capex incurred, civil works at 50%, and equipment procurement at \~40%. Commissioning is set for September 2027, with first commercial supply in Q4 FY29, adding a fourth growth platform in emerging regulated markets.